Rheumatology in Perspective · Olga Goodman, MD
Systemic Sjögren’s disease: an organ atlas for clinical decisions
Lungs, nerves, kidneys, vasculitis and lymphoid disease — from the clinical pattern to the next consequential decision.
Identify the organ lesion, establish a credible mechanism, recognise threats to function and choose an outcome that can show whether treatment is helping.
Understanding the assessment
Systemic disease: establish the lesion, the mechanism and the trajectory
Sjögren’s disease (SjD) can involve the lungs, peripheral and autonomic nerves, kidneys, skin and vessels, and lymphoid tissue. An organ manifestation may precede prominent sicca or become apparent years after the diagnosis. The practical task is to establish what is happening now: an inflammatory lesion, vascular injury, lymphoproliferation, persistent damage, a treatment complication, or a separate condition. These categories can coexist. A diagnostic label should narrow the investigation without closing the differential prematurely.
The intensity of dryness is a poor guide to the urgency of a new organ problem. Burning feet, exertional breathlessness, recurrent purpura, unexplained hypokalaemia and a persistent parotid mass require different pathways. Conversely, widespread pain and disabling fatigue do not by themselves establish vasculitis, interstitial lung disease (ILD) or inflammatory neuropathy. Symptoms deserve treatment even when the mechanism is not immune-mediated. [A01] [A02] [A09]
This atlas uses a consistent sequence: phenotype → objective evidence → competing causes → threat to function → treatment target → response measure. It is an educational reasoning framework by Olga Goodman, MD, not a validated diagnostic or prognostic score. It does not calculate an individual probability of systemic disease.
Back to contents ↑The organ map: what changes the next decision
| Clinical entry | Important distinctions | Useful next evidence |
|---|---|---|
| Cough or breathlessness | Airway disease, ILD, infection, pulmonary vascular disease, heart failure and treatment toxicity | Tempo, examination, oxygenation, complete PFTs, appropriately selected HRCT; cardiac/thromboembolic assessment when indicated |
| Burning, numbness, imbalance or weakness | Small versus large fibres; axonal versus demyelinating injury; length-dependent neuropathy versus ganglionopathy or mononeuritis multiplex | Neurological localisation, NCS/EMG, targeted skin/autonomic testing or selected tissue sampling |
| Electrolyte changes, stones, abnormal urine or declining filtration | Tubular dysfunction/TIN versus glomerular disease; autoimmune versus drug, vascular or metabolic causes | Potassium, bicarbonate, creatinine/eGFR, urinalysis and protein characterisation; nephrology and biopsy when it changes management |
| Purpura, ulceration or digital ischaemia | Skin-limited inflammation versus systemic vasculitis, thrombosis, embolism or another dermatological process | Lesion examination/biopsy, urine and renal tests, neurological and vascular assessment, correctly handled cryoglobulins |
| Persistent gland enlargement, nodes or monoclonal findings | Inflammatory sialadenitis, obstruction, infection, benign lymphoid proliferation and lymphoma | Trajectory, ultrasound/other targeted imaging, tissue architecture and haematopathology when indicated |
A symptom may lead to more than one row. Purpura plus new asymmetric weakness and haematuria, for example, raises a cross-organ vascular question; treating three separate symptoms can miss that relationship.
Back to contents ↑Attribution: an abnormal test is a starting point
Separate five statements in the record: the patient has SjD; an organ abnormality is present; its pattern is compatible with SjD; alternative causes have been assessed; and the balance of evidence supports SjD as the cause. The first two statements do not automatically prove the last. This matters when considering prolonged immunosuppression, when a treatment has substantial toxicity, and when a potentially malignant lesion could be obscured by empiric therapy.
Use a baseline against which change can be judged. A low DLCO needs interpretation alongside haemoglobin, lung volumes, emphysema and pulmonary vascular disease. Protein on dipstick does not identify the renal lesion. Reduced intraepidermal nerve fibre density supports small-fibre loss but does not specify its cause. Low C4 can strengthen an immune-complex hypothesis; it is neither a diagnosis of cryoglobulinaemic vasculitis nor a lymphoma test. [A02] [A09] [A16] [A18]
Avoid using a therapeutic response as retrospective proof. Glucocorticoids can improve several inflammatory disorders, and symptoms fluctuate. The stronger assessment combines a credible pretreatment phenotype with an objective functional trajectory and a response measure linked to the target organ. Failure to improve should trigger reassessment of attribution, reversibility, adherence, treatment exposure and competing pathology.
Back to contents ↑Lungs
Lungs: airways, interstitium, vessels and lymphoid tissue
Persistent cough may reflect airway dryness, bronchial hyperresponsiveness, bronchiectasis or small-airway disease, but also upper-airway cough syndrome, reflux, infection or a drug effect. Airway and interstitial disease may coexist. Obstruction, air trapping and recurrent infections should not be forced into an ILD-only model. A normal chest radiograph does not reliably exclude early interstitial abnormalities. [A02]
HRCT patterns include nonspecific interstitial pneumonia (NSIP), usual interstitial pneumonia (UIP), organising pneumonia and lymphoid interstitial pneumonia (LIP), sometimes with mixed features. Describe the dominant pattern, extent, fibrosis, traction bronchiectasis, cysts, nodules and their evolution. “Ground glass” is not synonymous with reversible inflammation: it can accompany fine fibrosis, infection, oedema or haemorrhage. “UIP pattern” is not synonymous with idiopathic pulmonary fibrosis when an autoimmune disease is present.
Research update — ACR 2026 abstract 1375: a retrospective multicentre ILD registry included 60 patients with SjD, 88 with rheumatoid arthritis and 10 with overlap disease. The primary abstract reports UIP in 32% of SjD-ILD versus 56% of RA-ILD; NSIP and LIP accounted for 45% and 13% in SjD. These selected registry data illustrate pattern diversity, not population prevalence or a comparative treatment effect. Continue to base decisions on the individual HRCT pattern, physiology and trajectory. [A26]
Cysts should be read in context. A cystic pattern compatible with LIP is not proof that every adjacent nodule is benign. Focal or enlarging lesions, a mass, consolidation that behaves atypically, or cysts with nodules may prompt evaluation for amyloid or lymphoproliferative disease. The imaging question is then broader than measuring the extent of inflammation. [A02]
A 2026 Chinese retrospective cohort associated radiological UIP with worse outcomes than non-UIP SjD-ILD, while UIP-SjD differed from idiopathic pulmonary fibrosis. The report is useful for recognising risk heterogeneity; its referral population, retrospective design and internal discrepancy between stated cohort totals argue against converting its survival figures into a bedside prediction. Its pulmonary-hypertension variable was echocardiographic and should not be equated with right-heart-catheterisation-confirmed pulmonary arterial hypertension. [A08]
If tissue identifies MALT lymphoma or amyloid, continue with the localized-versus-systemic assessment.
Back to contents ↑Lung investigations: function and structure answer different questions
In a patient with chronic cough or dyspnoea, the Sjögren’s pulmonary consensus supports complete pulmonary function testing and HRCT. “Complete” includes spirometry, lung volumes and diffusion capacity, not spirometry alone. Record test quality and comparable conditions; review the pattern and trend rather than reading one percentage in isolation. [A02]
For screening an asymptomatic person, weigh risk factors and the result’s likely consequence. ACR/CHEST recommends PFTs and HRCT for people with systemic autoimmune rheumatic diseases at increased ILD risk. ERS/EULAR supports considering HRCT in SjD with risk factors such as older age, male sex, active extrapulmonary disease or raised inflammatory markers. These are risk signals, not a rule that excludes ILD in a young woman or mandates the same scan schedule for everyone. [A03] [A04]
A low diffusion capacity with relatively preserved volumes may require attention to pulmonary vascular disease, anaemia or combined processes. Unexplained dyspnoea can require echocardiography; suspected pulmonary hypertension needs an appropriate specialist pathway. Sudden breathlessness, chest pain or new hypoxaemia demands an acute differential that includes pulmonary embolism, infection and cardiac disease.
Bronchoscopy and lavage are selective tools for questions such as infection, haemorrhage or an alternative diagnosis. Surgical lung biopsy is not a routine screening investigation. Discuss tissue sampling in a multidisciplinary setting when the expected result would materially change management. A radiological pattern, physiology and clinical context often supply enough information for a treatment decision. [A03] [A04]
After an informative biopsy, see how pulmonary MALT and amyloid change the next investigation.
Back to contents ↑Cysts plus a growing lung nodule: tissue before a convenient label
After a growing pulmonary nodule has been sampled, the pathology can redirect the case from an ILD pathway to MALT lymphoma, localized amyloid or both. The existing lung-imaging approach remains relevant; the next question is what the deposits mean beyond the sampled nodule. [A02]
If biopsy shows amyloid, ask what protein formed the deposits and whether the process is localized or systemic. A pathology series demonstrated frequent immunoglobulin light-chain, sometimes light- plus heavy-chain, deposition in nodular pulmonary amyloid associated with an indolent lymphoplasmacytic process. Local pulmonary AL-type deposits do not themselves establish systemic AL amyloidosis. [V08]
Systemic assessment should include serum and urine immunofixation and serum free light chains, with interpretation of the ratio in the context of renal function. Electrophoresis alone is insufficient. Evaluate possible cardiac, renal, hepatic and neurological involvement; additional tissue sampling and expert amyloid typing should answer residual uncertainty. An existing monoclonal gammopathy does not by itself prove that all deposits are AL or that all organ symptoms are amyloid. The 2026 ASH diagnostic guideline supports combining monoclonal-protein testing with tissue and organ assessment. [V09]
Back to contents ↑Lung follow-up: make guideline differences visible
| Source | Established SjD-ILD follow-up | How to interpret |
|---|---|---|
| ACR/CHEST 2023 guideline, published 2024 | Suggests PFTs every 3–12 months in the first year, then less often once stable; HRCT when clinically indicated | A flexible suggested range, not an evidence-proven optimal interval |
| ERS/EULAR guideline, first published online 2025; 2026 issue | Suggests PFTs every 3–6 months in the first year and at least every 6–12 months thereafter; repeat HRCT after 1–2 years in other CTD-ILD, particularly with greater risk or suspected progression | Recommendations for monitoring rest on very low-certainty evidence; tailor radiation exposure and the likelihood that imaging will change care |
| Individual clinical trajectory | Shorter reassessment for deterioration, a treatment change or discordant findings; longer intervals for durable stability | New symptoms override a previously reassuring calendar |
The differences support an explicit monitoring plan rather than an assertion that one schedule is universal. An abnormal result should be repeated or contextualised when quality, infection, anaemia or measurement variation could explain it. ACR/CHEST discourages using six-minute walk distance as a routine screening/monitoring test; ERS/EULAR discusses its role in severity and prognosis. These are partly different questions, and musculoskeletal limitations can distort walking performance. [A03] [A04]
Back to contents ↑Lung treatment: inflammation, progression and supportive care
Treatment depends on symptoms, physiological impairment, radiological extent, change over time and the consequences of waiting. Some limited, stable abnormalities warrant structured observation; clinically important or progressive disease may warrant immunomodulation. Mycophenolate and azathioprine are commonly used steroid-sparing options in SjD-ILD; rituximab or cyclophosphamide may enter decisions for selected severe or refractory disease. Choice must reflect the phenotype, comorbidities, infection risk, fertility/pregnancy considerations and other organ targets. [A02] [A05]
The direct SjD treatment evidence is much smaller than the breadth of routine prescribing suggests. A US retrospective ILD cohort included 19 patients, with seven exposed to mycophenolate and seven to azathioprine; physiological associations are encouraging but cannot establish a randomized comparative effect. ERS/EULAR’s recommendation for immunosuppression in SjD-ILD is conditional with very low certainty, explicitly recognising the scarcity of eligible direct comparative studies. [A06] [A04]
Progressive pulmonary fibrosis creates a separate antifibrotic question. The INBUILD autoimmune subgroup found a slower annual FVC decline with nintedanib, but only seven participants had Sjögren-related ILD. This supports an extrapolative discussion for a progressive fibrosing phenotype, not a claim of an adequately powered SjD-specific trial or reversal of established fibrosis. ACR/CHEST conditionally recommends against first-line nintedanib for SjD-ILD while allowing it as an option after progression; this differs from calling it ineffective for all SjD-associated fibrosis. [A07] [A05]
Supportive care remains part of treatment: vaccination and infection prevention, smoking cessation, pulmonary rehabilitation when appropriate, oxygen for documented need, airway clearance for clinically relevant bronchiectasis, and management of reflux/aspiration when supported by findings. With acute deterioration, assess infection, thromboembolism, oedema and drug toxicity alongside inflammatory exacerbation; simply escalating steroids can miss the actionable cause.
Back to contents ↑Nervous system
Peripheral nerves: localise before labelling
| Pattern | Clinical clues | Key implication |
|---|---|---|
| Small-fibre neuropathy | Burning, painful cold, electric sensations, allodynia; patchy or distal distribution; possible autonomic symptoms | Routine NCS can be normal; small-fibre testing addresses a different compartment |
| Length-dependent large-fibre polyneuropathy | Distal numbness, reduced vibration, loss of reflexes and sometimes weakness | NCS/EMG helps define axonal versus demyelinating features and competing causes |
| Sensory ganglionopathy/neuronopathy | Marked proprioceptive loss, sensory ataxia, non-length-dependent or asymmetric sensory abnormalities | Loss of sensory neurons may become disabling; prompt specialist assessment matters |
| Vasculitic neuropathy | Painful acute/subacute or stepwise deficits, asymmetry, foot/wrist drop, mononeuritis multiplex | Potentially time-sensitive ischaemic axonal injury; assess systemic vasculitis and plan tissue investigation |
| Demyelinating polyradiculoneuropathy | Progressive weakness and sensory changes with an appropriate electrodiagnostic pattern | Assess accepted CIDP or other syndrome criteria; the SjD label does not substitute for neurological classification |
| Focal entrapment or radiculopathy | Anatomical nerve/root distribution, mechanical contributors | Common conditions remain common and may require local treatment rather than systemic immunosuppression |
Pain severity alone does not localise the lesion. Document symmetry, distribution, onset, motor involvement, reflexes, vibration/proprioception, pain/temperature sensation, cranial signs and gait. Review diabetes, B12 deficiency, thyroid disease, paraproteinaemia, alcohol, kidney disease, medications and supplements, including excessive B6 exposure. [A09]
Back to contents ↑Small-fibre disease: why a normal EMG can coexist with neuropathy
Nerve conduction studies mainly interrogate larger myelinated fibres; needle EMG adds information about motor units. They can be useful for excluding a competing large-fibre or motor process while remaining normal in isolated small-fibre neuropathy. The conclusion should specify what the study did and did not test. “Normal EMG” should not be used as a universal synonym for “normal nerves.”
Selected patients may need skin punch biopsy for intraepidermal nerve fibre density, quantitative sensory testing or autonomic studies. These approaches have different strengths and limitations. Interpretation requires an appropriate sampling site, laboratory norms, clinical pattern and awareness that no single result assigns the neuropathy to SjD. An isolated abnormal biopsy is not a prescription for immunotherapy.
In the French prospective series of 40 SjD-associated small-fibre cases, neuropathy was defined using symptoms with normal conduction studies plus small-fibre physiological abnormalities or reduced fibre density. Anti-SSA was less frequent than in SjD controls without neuropathy. This finding challenges an antibody-only exclusion strategy but does not mean that every seronegative burning-pain syndrome is SjD or that antibody status determines an individual treatment response. [A10]
Follow pain, sleep, allodynia, orthostatic or sweating symptoms and function. Objective testing may support the diagnosis, while repeated biopsy is not automatically the most informative response measure. Record tolerability of pain medications: sedation, disequilibrium, constipation and dryness may change the net benefit even when pain decreases.
For the next diagnostic decision, see B6 exposure and neuropathy with an IgM band.
Back to contents ↑Burning feet: ask what a supplement contributes
Vitamin B6 may be hidden in a B-complex, magnesium product or several overlapping preparations. Excess supplemental pyridoxine can cause a sensory neuropathy; a daily dose of 200 mg deserves immediate attention. Regulatory adverse-event reports also describe neuropathy with lower doses and combined products, so a modest dose on one bottle does not settle the question. Stop unnecessary B6 exposure and follow symptoms and neurological findings. A raised B6 concentration supports exposure but does not prove that every neurological feature has the same cause. Continuing the diagnostic assessment matters when weakness, asymmetry, systemic inflammation or autonomic dysfunction is present. [V01]
Back to contents ↑An IgM-kappa band changes the differential, not the diagnosis by itself
A monoclonal band and neuropathy can coexist incidentally. Establish whether the neurological phenotype matches a plausible antibody-mediated or deposit-related process. Serum immunofixation characterizes the band; electrodiagnostic findings help determine whether the lesion is demyelinating, axonal or mixed. Slowly evolving distal sensory loss with demyelination raises an anti-myelin-associated glycoprotein (anti-MAG) question. The EAN/PNS guideline advises anti-MAG testing when an IgM paraprotein accompanies a CIDP-like presentation, particularly a distal phenotype. A convincingly high result must still be interpreted with the clinical and electrophysiological picture. [V02]
Do not let “IgM neuropathy” close a different diagnostic problem. Rapid painful weakness with purpura and low complement requires assessment for cryoglobulinemic vasculitis. Marked autonomic involvement, otherwise unexplained organ dysfunction or a new focal lesion should reopen the questions of amyloid, infiltrative disease and other causes. Neurology and hematology need the same account of tempo, disability and organ findings; the monoclonal protein concentration alone does not explain them. [A09] [V04]
Back to contents ↑Neuropathy treatment: distinguish symptom relief from immune treatment
The PNS guideline (first published online 2025; 2026 issue) is a major practical advance but should be read with its evidence base in view: the review found six case series, one retrospective cohort and two prospective cohorts without comparison groups. Strong recommendations sometimes reflect the potential harm of delay, not high-certainty randomized efficacy. This distinction is especially important when counselling about immunoglobulin or B-cell therapy. [A09]
For neuropathic pain, gabapentin, pregabalin and SNRIs are options, chosen with renal function, falls, sleep, mood and adverse effects in mind. Tricyclics and other agents require attention to anticholinergic burden and dryness. Analgesic response can be valuable independently of whether the underlying immune process is active.
For severe, recent-onset or progressive small-fibre neuropathy credibly attributed to an immune mechanism and unresponsive to symptomatic treatment, the guideline supports considering immunoglobulin. This is a conditional recommendation; establish an observable goal and reassessment plan. For suspected vasculitic neuropathy, the same guideline prioritises rapid immune treatment, including glucocorticoids with rituximab, rather than treating it as a pain-only syndrome or using IVIG as the default first-line strategy. Diagnostic sampling should be coordinated without allowing avoidable delay in a threatening presentation. [A09]
The French AIR registry illustrates why phenotype matters: at three months, reported neurological benefit with rituximab occurred in 9/10 patients with vasculitis or cryoglobulinaemia versus 2/7 without those features. With 17 selected patients and no randomized control, those proportions are not reliable personal response probabilities. They support a mechanistic distinction rather than a general claim that rituximab treats all SjD neuropathies. [A12]
Sensory ganglionopathy deserves particular urgency when gait or proprioception is deteriorating. A 13-case French series documented chronic disability and heterogeneous treatment responses; it cannot determine the best regimen. Early treatment, rehabilitation, fall prevention and appropriate aids address different parts of the problem. Persistent deficits after inflammatory control may represent damage and should not automatically trigger indefinite treatment escalation. [A11]
For tissue selection and the distinction between maintenance and residual pain, see the nerve-biopsy decision. For immunoglobulin risks and replacement, see two different immunoglobulin indications.
Back to contents ↑What a nerve biopsy can—and cannot—settle
When suspected vasculitic neuropathy needs tissue confirmation, select an affected sensory nerve with clinical and electrodiagnostic guidance. A superficial peroneal nerve biopsy with peroneus brevis muscle sampling is an established approach, not a mandatory site for every patient. In a 70-biopsy series, the sensitivity of definite vasculitis was only about 60%. The lesion is patchy: a negative specimen cannot reliably erase a strong clinical diagnosis. Conversely, perivascular inflammation alone is less convincing than inflammation accompanied by vessel-wall injury and compatible ischaemic nerve changes. [V05] [V06]
Arrange sampling with a team experienced in nerve pathology and discuss persistent numbness or neuropathic pain from the procedure. Tissue plans should not create avoidable delay when new motor loss threatens function. For Sjögren-associated vasculitic neuropathy, the PNS guideline supports urgent glucocorticoids with rituximab; evidence certainty is very low. It also conditionally supports subsequent maintenance immunomodulation. Maintenance and analgesia answer different questions: preventing another ischaemic injury is not the same as escalating immune treatment until every residual pain disappears. [A09]
Back to contents ↑Autonomic dysfunction: characterise the physiology
Orthostatic lightheadedness, tachycardia, altered sweating, heat intolerance, gastrointestinal dysmotility and bladder symptoms may suggest autonomic dysfunction. These symptoms are not specific. Review dehydration, anaemia, endocrine disease, medications, deconditioning, arrhythmia and other causes. A symptom questionnaire can organise the history; it cannot establish autoimmune autonomic neuropathy.
Start with a coherent account of posture, triggers, heart-rate and blood-pressure behaviour and accompanying symptoms. Selected patients need formal testing, such as tilt testing, heart-rate variability, sudomotor assessment and Valsalva responses. A Korean cohort of 154 patients used physiological heart-rate-variability measures; its findings should not be treated as equivalent to the prevalence of clinically diagnosed POTS or autonomic failure in another clinic. [A13]
Nonpharmacological and pharmacological choices depend on the physiology. Additional fluids, salt, compression and adapted exercise may be useful in selected orthostatic syndromes, but fluid/salt loading is inappropriate as a blanket instruction in kidney disease, heart failure, uncontrolled hypertension or certain electrolyte disorders. Severe, progressive immune-mediated autonomic dysfunction may justify discussion of immunotherapy in specialist care after alternative explanations and symptomatic measures have been considered. [A09]
Back to contents ↑Central neurological symptoms: preserve the differential
Brain fog and cognitive fatigue deserve a structured assessment of sleep, pain, mood, medication effects, anaemia and endocrine disease as well as neurological examination when indicated. They do not themselves establish inflammatory CNS disease. Nonspecific white-matter lesions also need age, vascular risk and migraine context; an MRI abnormality is not automatically “CNS Sjögren’s.”
Optic neuritis, a myelopathic syndrome, seizures or a focal deficit require an appropriate neurological pathway. Demyelinating disease, infection, vascular events and overlapping autoimmune syndromes may need separate investigation. The PNS guideline addresses peripheral and autonomic disease; its recommendations should not be repurposed as evidence for CNS treatment. Sudden stroke-like symptoms require emergency assessment rather than waiting to resolve autoimmune attribution. [A25]
Back to contents ↑Kidneys
Kidneys: filtration and tubular function are different
The familiar creatinine/eGFR measures predominantly describe filtration. Tubules also regulate acid, potassium, phosphate, water and other solutes. A patient can have a tubular disorder before a striking creatinine rise. SjD renal disease includes tubulointerstitial nephritis (TIN) and less commonly glomerular lesions; the latter may involve immune complexes, cryoglobulins or an associated process.
Distal renal tubular acidosis (dRTA) is a key pattern: impaired acid excretion can cause a normal-anion-gap metabolic acidosis, often with hypokalaemia, and predispose to stones or nephrocalcinosis. Clinical clues include weakness, cramps, recurrent stones and sometimes hypokalaemic paralysis. A urine pH measured in isolation does not diagnose dRTA: systemic acid-base status, infection, medications and sample quality matter.
Incomplete dRTA describes impaired urinary acidification without overt systemic acidosis and may require specialist physiological testing. In a Dutch study of 57 pSS patients, complete and incomplete forms were identified under a defined testing protocol. This does not support home acid-loading tests or a universal screening challenge. An Indian prospective referral cohort found a much greater burden of renal involvement, frequently presenting with hypokalaemic weakness; different ascertainment and selection explain part of the contrast. [A14] [A15]
Proximal tubular dysfunction can add phosphate loss, low-molecular-weight proteinuria or other solute abnormalities. Bone pain or weakness therefore needs consideration of mineral and acid-base disturbances alongside inflammatory muscle disease or osteoporosis. Correcting the biochemical defect and deciding whether active TIN requires immune treatment are related but separate tasks. [A16]
Back to contents ↑Renal assessment: read the urine as well as the creatinine
| Finding | Question it raises | Next distinction |
|---|---|---|
| Low potassium or bicarbonate | Renal tubular loss, acid-base disorder, gastrointestinal loss or medication effect? | Assess severity, ECG when appropriate, repeat chemistry and targeted urine/acid-base studies |
| Haematuria with proteinuria or casts | Glomerular disease, infection, stone, urological source or another lesion? | Urine microscopy, quantitative protein/albumin, trajectory of filtration, complement/cryoglobulins and nephrology |
| Total protein greater than expected from albumin | Tubular or overflow protein rather than predominantly albumin? | Selected protein characterisation; a standard dipstick may miss relevant non-albumin protein |
| Rising creatinine | Inflammation, obstruction, volume disturbance, nephrotoxicity or vascular disease? | Medication/volume review, urine and imaging; tissue diagnosis if needed for a consequential decision |
Renal biopsy is considered when the lesion, severity or uncertainty would change treatment, particularly with significant proteinuria, active sediment, declining renal function or possible overlapping disease. A SjD diagnosis does not make every glomerular lesion autoimmune SjD nephritis. Pathology may redirect the discussion toward monoclonal disease, membranous nephropathy, another glomerulonephritis or chronic noninflammatory injury. [A16] [A17]
The 2026 Mayo Clinic (US) biopsy cohort characterises patients who reached a biopsy threshold, not the frequency of kidney disease among all people with SjD. Biopsy-selected percentages must not be used as general counselling risks. The distinction between TIN and glomerular disease is more portable than the exact frequency reported by any single referral centre.
For a monoclonal band with organ injury, see why a small marrow clone may still matter.
Back to contents ↑A small marrow clone can still produce major organ injury
“Clonal B cells, no overt lymphoma” is a meaningful result, not a reassurance that the monoclonal protein is harmless. A small clone may produce a nephrotoxic immunoglobulin even when it does not meet criteria for treatment of a hematological malignancy. This is the central distinction behind monoclonal gammopathy of renal significance. Kidney biopsy determines the lesion; serum and urine immunofixation, free light chains, marrow assessment and flow cytometry help connect it to the clone. [V04]
In a patient with an IgM-kappa band, type II cryoglobulins and a membranoproliferative lesion, rheumatology, nephrology and hematology should review the tissue and hematological findings together. The management question is whether the clone or its protein is driving injury. Do not use the absence of bulky lymphoma as a reason to ignore that possibility, or use a monoclonal band alone to declare that every kidney lesion is clonal. [V04]
Back to contents ↑Renal treatment: correct physiology and target active disease
Severe hypokalaemia, arrhythmia, profound weakness or rapidly declining renal function may require urgent monitored treatment. Potassium and alkali replacement must be coordinated; in a hypokalaemic patient, introducing alkali without appropriate potassium management can aggravate the deficit. Replacement is an individual prescription based on kidney function, laboratory values and the cause, not a self-directed supplement experiment.
Active TIN may warrant glucocorticoids with a steroid-sparing agent, whereas chronic scarring limits recoverability. A UK series of 12 biopsy-confirmed cases associated treatment, usually mycophenolate with corticosteroids, with improved renal function. Its small uncontrolled design supports a treatment rationale but cannot tell us the magnitude of causal benefit, the optimal duration or which patient requires the same regimen. [A16]
Glomerular disease is treated according to pathology and mechanism. Cryoglobulinaemic glomerulonephritis requires an immune-complex and B-cell evaluation, and may require a different approach from isolated dRTA. Monitoring should pair filtration and urinary findings with the relevant electrolytes and bicarbonate; a better creatinine does not prove all tubular defects have resolved. Drug dosing, avoidance of nephrotoxins and blood-pressure management remain important regardless of the immune regimen.
Back to contents ↑Blood vessels
Skin and vessels: distinguish purpura from systemic vasculitis
Palpable purpura, often on dependent lower limbs, can be a clue to small-vessel inflammation. Photographs and examination during an active episode can be more useful than a vague record of “rash.” A selected fresh lesion may warrant biopsy with appropriate processing, including direct immunofluorescence when indicated. Biopsy establishes the cutaneous pattern; it does not alone determine whether the kidneys, nerves or gut are involved.
Consider medication reactions, infections, thrombocytopenia, venous/stasis changes and other dermatological causes. Livedo, ulcers and ischaemic digits also require assessment for thrombotic, embolic and macrovascular disease; not every vascular-looking lesion is inflammatory. New severe digital pain, colour change, coldness or threatened tissue viability requires prompt vascular assessment.
Cryoglobulinaemic vasculitis is an important SjD phenotype because immune complexes can link purpura with neuropathy, glomerular injury and systemic disease. Low C4, RF, circulating cryoglobulins and monoclonal findings can strengthen suspicion but do not replace clinical assessment. A Spanish cohort of 515 patients separated circulating cryoglobulins from clinical cryoglobulinaemic vasculitis; they were not interchangeable categories and carried different outcome associations. [A18]
Look actively for cross-organ combinations: purpura plus a new foot drop; purpura plus haematuria; recurrent ulcers with a monoclonal component; or systemic symptoms accompanying gland enlargement. These combinations can change the urgency, scope of tissue investigation and treatment target. Skin-limited disease and organ-threatening vasculitis should not be presented as one treatment category.
When purpura accompanies new asymmetric weakness, see choosing nerve and muscle tissue.
Back to contents ↑Cryoglobulins: a negative result can be a specimen problem
Cryoglobulins are immunoglobulins that precipitate under defined cold conditions and redissolve on warming. Testing is unusually sensitive to handling. Collection, transport, clotting and separation require laboratory-specific temperature control, typically maintaining the early stages around 37°C before the controlled cold-incubation phase. Routine phlebotomy transport can therefore produce a misleading negative result.
When the phenotype is convincing, discuss the protocol with the laboratory and consider repeat testing under validated conditions. Request interpretation of cryoglobulin type and associated immunofixation as appropriate. Complement and RF are supporting clues, not substitute diagnostic assays. A cryocrit percentage is not a stand-alone measure of the severity of organ injury. [A19]
Investigate potential drivers, including hepatitis C and other infections where clinically relevant, as well as a clonal B-cell disorder. Treatment planning depends on the driver and the organ threat. Severe renal, neurological or other life-threatening immune-complex disease can require urgent multidisciplinary treatment; the underlying B-cell, autoimmune or infectious process must be addressed alongside the threatened organ. [A18] [A09]
Before considering immunoglobulin in a patient with this history, review cryoglobulinemic risk and antibody replacement.
Back to contents ↑Glands & lymphoma
Lymphoma: recognise a pattern without turning risk into destiny
SjD is associated with increased B-cell lymphoma risk, particularly salivary-gland MALT lymphoma. Absolute risk varies with cohort, duration and phenotype; most people with SjD do not develop lymphoma. A general lifetime estimate and a risk percentage from a selected case-control model answer different questions and should not be exchanged. Several abnormalities increase concern when persistent or clustered, but none is diagnostic alone.
Features that deserve attention include persistent or asymmetric gland enlargement, a focal mass, lymphadenopathy, splenomegaly, unexplained constitutional symptoms, falling blood counts, a monoclonal component, cryoglobulinaemia and low complement. Compare serial observations: transient swelling around an infection is different from a growing unilateral lesion. In a European case-control study, the duration and timing of parotid swelling carried useful associations, supporting careful history rather than a binary “swelling: yes/no” entry. [A20]
Reactive polyclonal hypergammaglobulinaemia should be distinguished from a monoclonal protein. Even a monoclonal finding does not establish malignancy: clinical context, concentration, light-chain interpretation, urine studies where appropriate and the associated organ phenotype determine the next investigation. Do not reassure solely because a gland is painless or because an earlier lip biopsy was benign.
Risk discussions should give a concrete plan: which symptom changes prompt an earlier examination; what the current abnormality means; whether imaging or tissue is warranted; and who will review the result. Repeating frightening percentages without a monitoring strategy adds anxiety without improving recognition. [A01] [A20]
The distinction between overt lymphoma and a pathogenic small clone is explained in small clones and organ injury.
Back to contents ↑Lymphoma investigation: choose the right target and specimen
Persistent gland swelling may arise from inflammation, obstruction or infection as well as lymphoma. Targeted ultrasound helps characterise diffuse versus focal changes and choose a sampling target. The clinical question determines whether further imaging, haematology assessment or biopsy is appropriate. PET/CT can be useful in selected diagnostic or staging situations; it is not a routine annual screening test for every person with SjD.
Suspected lymphoma requires enough material for architecture and appropriate immunophenotyping. A fine-needle aspirate alone may be insufficient. Image-guided core biopsy can provide useful information in experienced centres, with samples coordinated for histology and flow cytometry when appropriate. In a US series, ultrasound-guided core sampling facilitated evaluation of suspected salivary lymphoma; this does not eliminate sampling error or establish one procedure as correct for every lesion. Persistent clinical concern after a nondiagnostic result requires reassessment of the target and tissue strategy. [A22]
Do not perform a routine minor lip biopsy as though it were a substitute for investigating a new parotid mass. Similarly, clonal B cells are an important finding that needs architectural and clinical context, not an isolated synonym for lymphoma. A haematopathologist’s integrated interpretation matters.
A German retrospective study of 134 patients covering 1,031 patient-years found no lymphomas through 569 asymptomatic screening ultrasound examinations, whereas clinically triggered examinations had diagnostic yield. It argues against indiscriminate repetitive screening in the studied low-suspicion setting; it does not argue against imaging a new mass, clinically active disease or a changing risk profile. A normal previous ultrasound does not close a new diagnostic question. [A21]
For a pulmonary biopsy showing both lymphoid disease and deposits, see MALT lymphoma, amyloid typing and systemic assessment.
Back to contents ↑Decisions & follow-up
Urgency: act on the syndrome before resolving every label
| Presentation | Action principle | Do not assume |
|---|---|---|
| Sudden focal deficit, loss of vision, rapidly progressive weakness, new bladder dysfunction with spinal signs | Emergency evaluation using the relevant neurological pathway | That a known autoimmune disease explains a stroke-like or cord syndrome |
| Severe breathlessness, hypoxaemia, haemoptysis, acute chest pain | Urgent cardiopulmonary assessment; stabilise and evaluate infection, embolism, oedema, haemorrhage and inflammatory disease | That it is ordinary sicca-related cough or a routine flare |
| Severe weakness with major potassium disturbance, arrhythmia, oliguria or rapidly deteriorating kidney function | Urgent monitored biochemical and renal assessment | That a normal earlier creatinine excludes an acute tubular problem |
| Painful asymmetric nerve deficits, new foot/wrist drop or threatened digital tissue | Prompt assessment for ischaemic/vasculitic injury; coordinate neurology and vascular/rheumatology expertise | That symptomatic pain treatment alone protects function |
| Persistent or enlarging gland mass, nodes or unexplained systemic symptoms | Expedited diagnostic assessment and an explicit tissue/imaging plan when indicated | That every swelling is lymphoma or that painless swelling is harmless |
These categories are intended to clarify urgency, not to set a universal waiting period. Severity, speed of change and local emergency pathways determine the care setting. For detailed disease-specific emergency frameworks, see True Rheumatic Emergencies and the vasculitis module.
Back to contents ↑A useful longitudinal record: follow the organ and the person
For each active problem, document the baseline phenotype, evidence for attribution, important alternatives, current functional threat, treatment goal and reassessment trigger. For lungs, this may mean comparable FVC/DLCO and imaging trajectory; for nerves, strength, sensory distribution, gait and pain/function; for kidneys, eGFR, protein/urine findings and electrolytes; for vascular disease, new lesions and organ involvement; for glandular lesions, size, duration and tissue findings.
Distinguish three outcomes: suppressing active injury, preventing further loss, and recovering function. Recovery can lag behind disease control; some damage may persist. Pain and fatigue can continue even when organ inflammation improves. Conversely, a patient may feel comparatively well while surveillance identifies a relevant renal or pulmonary change. A single global score should not substitute for this organ-level record.
Treatment monitoring also needs its own line: infection, blood counts, liver or kidney toxicity, blood pressure, reproductive issues and adverse effects relevant to the selected drug. The same symptom can represent disease, treatment or a third cause. Record what would trigger dose adjustment, further testing, a different specialist or hospital assessment rather than simply writing “monitor.”
Back to contents ↑Interpreting evidence
International evidence: compare populations, not flags
The atlas draws on American multidisciplinary guidance and cohorts, European recommendations and studies, and Asian and Latin American primary data. Their differences are informative only when definitions and selection are visible. Renal acidification testing can detect abnormalities missed by routine creatinine; a biopsy registry enriches for clinically important kidney disease; a neuropathy referral centre enriches for difficult neurological presentations. None directly estimates prevalence in an unselected community population.
The Big Data Sjögren Project’s 8,310-patient analysis associated phenotype with geolocation and ethnicity. The Brazilian BRAS registry adds a substantial Latin American clinical perspective. Such descriptive work supports broader representation, while differences in referral, disease duration, testing, classification and access remain possible explanations. Avoid presenting ethnicity as a deterministic biological prognosis or importing one centre’s survival curve into personal counselling. [A23] [A24]
Two guideline dates can also mislead. A guideline called “2023” may be published in 2024; a 2026 journal issue can contain work first released online earlier. The evidence-search cut-off may be earlier still. This atlas identifies the document rather than assuming the newest publication year means every recommendation incorporates the newest trial.
Back to contents ↑Open questions and therapeutic pipelines: what organ claims still need proof
Precision phenotypes. There is a plausible future in linking tissue inflammation, B-cell activation, immune complexes and neural injury to treatment choice. To become clinically useful, a biomarker must predict outcomes beyond what is already known and improve a prospective treatment decision. A cluster discovered after the fact does not yet select a patient for a drug.
Reversibility. In glandular, neural, pulmonary and renal tissue, an unresolved question is how early suppression of injury translates into preserved function. Objective longitudinal measures and appropriate controls are required to separate prevention of damage from symptom relief or regression to the mean. Regeneration claims require evidence of restored function, not only a laboratory signal.
Organ-specific efficacy. A trial improving a composite SjD activity score does not necessarily establish benefit in vasculitic neuropathy, glomerulonephritis, progressive fibrosis or lymphoma. Severe organ phenotypes may be excluded or represented by very few participants. New B-cell, FcRn, CD40/CD40L and cellular approaches should be evaluated against the actual enrolled population, organ-domain outcomes, rescue treatment, safety and follow-up. This is a question to ask of the pipeline, not a claim that a particular emerging therapy is proven across this atlas.
Better monitoring. Priorities include validated risk-stratified lung surveillance, diagnostic standards for small-fibre/autonomic disease, renal tubular detection strategies and a lymphoma surveillance approach that balances early recognition with false-positive investigations. A more intensive test schedule is not automatically a better one. [A04] [A09] [A21]
Back to contents ↑Sources and evidence · 32
Publication titles are retained in their original language. The evidence type describes the source, not a guarantee of certainty. Abstract-only sources were not treated as full-text reviews.
- A01 British Society for Rheumatology guideline on management of adult and juvenile onset Sjögren disease.
2025 · Clinical guideline / consensus · United Kingdom · Full text consulted - A02 Consensus Guidelines for Evaluation and Management of Pulmonary Disease in Sjögren’s.
2021 · Clinical guideline / consensus · United States · Full text consulted - A03 2023 American College of Rheumatology (ACR)/American College of Chest Physicians (CHEST) Guideline for the Screening and Monitoring of Interstitial Lung Disease in People with Systemic Autoimmune Rheumatic Diseases.
2024 · Clinical guideline / consensus · United States · Full text consulted - A04 ERS/EULAR clinical practice guidelines for connective tissue disease-associated interstitial lung disease.
First published online 2025; 2026 issue · Clinical guideline / consensus · Europe · Full text consulted - A05 2023 American College of Rheumatology (ACR)/American College of Chest Physicians (CHEST) Guideline for the Treatment of Interstitial Lung Disease in People with Systemic Autoimmune Rheumatic Diseases.
2024 · Clinical guideline / consensus · United States · Full text consulted - A06 Treatment of primary sjögren’s syndrome-related interstitial lung disease: a retrospective cohort study.
2020 · Retrospective cohort · United States · Full text consulted - A07 Nintedanib in Patients With Autoimmune Disease-Related Progressive Fibrosing Interstitial Lung Diseases: Subgroup Analysis of the INBUILD Trial.
2022 · Randomized trial subgroup · International · Full text consulted - A08 Clinical significance of radiological usual interstitial pneumonia pattern in primary Sjögren syndrome-associated interstitial lung disease.
2026 · Retrospective cohort · China · Full text consulted - A09 Clinical Practice Guideline for Evaluation and Management of Peripheral Nervous System Manifestations in Sjögren’s Disease.
First published online 2025; 2026 issue · Clinical guideline / consensus · United States · Full text consulted - A10 Sjögren Syndrome-Associated Small Fiber Neuropathy: Characterization From a Prospective Series of 40 Cases.
2013 · Prospective cohort · France · Full text consulted - A11 Sjögren Sensory Neuronopathy (Sjögren Ganglionopathy): Long-Term Outcome and Treatment Response in a Series of 13 Cases.
2016 · Uncontrolled case series · France · Full text consulted - A12 Efficacy of rituximab in primary Sjogren’s syndrome with peripheral nervous system involvement: results from the AIR registry.
2012 · Registry analysis · France · Abstract consulted - A13 Autonomic dysfunction in primary Sjogren’s syndrome: a prospective cohort analysis of 154 Korean patients.
2017 · Observational cohort · South Korea · Full text consulted - A14 Renal involvement in primary Sjogren’s syndrome: a prospective cohort study.
2018 · Prospective cohort · India · Abstract consulted - A15 Prevalence of distal renal tubular acidosis in primary Sjögren’s syndrome.
2015 · Diagnostic physiology study · Netherlands · Abstract consulted - A16 Tubulointerstitial nephritis in primary Sjögren syndrome: clinical manifestations and response to treatment.
2016 · Uncontrolled case series · United Kingdom · Full text consulted - A17 Clinicopathologic Features and Prognostic Factors in Biopsy-Confirmed Renal Involvement in Primary Sjőgren Syndrome.
2026 · Retrospective cohort · United States · Full text consulted - A18 Cryoglobulinaemic vasculitis at diagnosis predicts mortality in primary Sjögren syndrome: analysis of 515 patients.
2016 · Observational cohort · Spain · Abstract consulted - A19 Practical Details for the Detection and Interpretation of Cryoglobulins.
2022 · Laboratory methods recommendations · France · Abstract consulted - A20 Predicting lymphoma in Sjögren’s syndrome and the pathogenetic role of parotid microenvironment through precise parotid swelling recording.
2023 · Case-control study · Europe · Full text consulted - A21 Lymphoma in Sjögren’s syndrome: no need for repetitive screening ultrasounds of the major salivary glands and neck in asymptomatic patients.
2025 · Retrospective cohort · Germany · Abstract consulted - A22 Ultrasound-Guided Biopsy of Suspected Salivary Gland Lymphoma in Sjögren’s Syndrome.
2021 · Diagnostic procedure series · United States · Full text consulted - A23 Influence of geolocation and ethnicity on the phenotypic expression of primary Sjögren’s syndrome at diagnosis in 8310 patients: a cross-sectional study from the Big Data Sjögren Project Consortium.
2017 · Registry analysis · International · Abstract consulted - A24 Brazilian Registry of Sjögren’s Disease (BRAS): a full picture of Sjögren’s disease in Brazil.
2025 · Registry analysis · Brazil · Full text consulted - A25 Neurologic Complications — Johns Hopkins Sjögren’s Center
· Academic clinical education · United States · Full text consulted - A26 Distinct ILD phenotypes across rheumatoid arthritis, Sjögren disease and RA–Sjögren overlap: multicenter registry findings.
ACR 2026, abstract 1375 · Retrospective registry · Conference abstract - [V01] TGA. Peripheral neuropathy with supplementary vitamin B6; updated 2026.
- [V02] EAN/PNS guideline on CIDP, second revision (2021).
- [V04] IKMG consensus on monoclonal gammopathy of renal significance (2019).
- [V05] Superficial peroneal nerve/peroneus brevis biopsy study (2000).
- [V06] Peripheral Nerve Society vasculitic neuropathy guideline (2010).
- [V08] Nodular pulmonary amyloidosis: pathological series (2013).
- [V09] ASH guideline on diagnosis of AL amyloidosis (2026).
No symptoms or personal health information are collected by this reading page.